CEL-SCI reports on adjuvant properties of CEL-1000 peptide to enhance vaccines
Zimmerman: "CEL-1000 does not appear to induce self- directed or cross-reactive antibodies, can be well characterized and is inexpensive to manufacture."
06-Jun-2003 -
Dr. Daniel Zimmerman, Senior Vice President of Research, Cellular Immunology at CEL-SCI Corporation today reported at the conference Modern Vaccines, Adjuvants and Delivery Systems in Dublin, Ireland on the potential use of the Company's CEL-1000 peptide as an adjuvant for vaccines. Adjuvants are ...
adjuvants
antibodies
encephalitis
+8